A Long-Term Safety Follow-up Registry for Patients Who Received Treatment With Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa (RDEB) in the Post-Marketing Setting

NCT07700966 · clinicaltrials.gov ↗

RECRUITING

Status

250

Enrollment

INDUSTRY

Sponsor class

Conditions

Recessive Dystrophic Epidermolysis Bullosa

Interventions

COMBINATION_PRODUCT: Prademagene Zamikeracel

Sponsor

Abeona Therapeutics, Inc